The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NAMS | +92.11% | N/A | N/A | +274% |
| S&P | +13% | +86.41% | +13.26% | +73% |
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.35M | -98.8% |
| Gross Profit | $0.28M | -99.0% |
| Gross Margin | 81.61% | -18.3% |
| Market Cap | $3.20B | 114.4% |
| Market Cap / Employee | $35.59M | 0.0% |
| Employees | 90 | 0.0% |
| Net Income | -$72.01M | -332.5% |
| EBITDA | -$55.08M | -126.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $539.72M | 27.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.09M | -68.0% |
| Short Term Debt | $0.18M | -24.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -36.08% | 0.0% |
| Return On Invested Capital | -31.61% | -0.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$32.81M | -160.9% |
| Operating Free Cash Flow | -$32.77M | -162.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 6.25 | 2.92 | 2.61 | 4.11 | 6.57% |
| Price to Sales | 54.73 | 50.43 | 33.54 | 96.03 | - |
| Price to Tangible Book Value | 6.26 | 2.92 | 2.61 | 4.11 | 6.49% |
| Enterprise Value to EBITDA | -38.44 | -22.78 | -39.57 | -48.66 | 2.92% |
| Return on Equity | -31.5% | -28.4% | -39.9% | - | |
| Total Debt | $0.45M | $0.39M | $0.33M | $0.27M | -47.43% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
